Views Navigation

Event Views Navigation


Dialogues in Waldenström’s Macroglobulinemia: A Canadian Policy Summit

Beigene, the company that created Zanubrutinib (Brukinsa), is sponsoring a session through the organization Catalytic Health.  To quote from their invitation: Who Should Attend? This non-promotional session aims to facilitate the dialogue around Waldenström’s Macroglobulinemia between Canadian healthcare professionals, policy experts, patients and representatives from patient advocacy groups. As such, the session is geared towards medical oncologists/hematologists, nurses, pharmacists who treat patients with Waldenström’s Macroglobulinemia, members of the patient community and policy makers whose work may touch on cancer initiatives. The Summit details: Join us for a live, virtual and interactive program to hear from Canadian clinical and policy experts as [...]

Go to Top